Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells : Sensitivity of ovarian cancer cells to phyto-active chemicals

Cell Biology and Toxicology

Volumn 27, Issue 2, 2011, Pages 133-147

  Chen, Sophie ^a   Cooper, Matt ^b   Jones, Matt ^b   Madhuri, Thumuluru Kavitha ^c   Wade, Julie ^b   Bachelor, Ashleigh ^b   Butler Manuel, Simon ^c,d  

^a Ovarian and Prostate Cancer Research Trust Laboratory   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d Guildford Nuffield Hospital   (United Kingdom)

Author keywords

Anti proliferative activity; Apoptosis; Cell cycle; Oridonin; Ovarian cancer; Wogonin

Indexed keywords

CARBOPLATIN; LETROZOLE; ORIDONIN; PACLITAXEL; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; PROTEIN P53; WOGONIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES FLUID; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER STAGING; CELL LINE; CELL STRAIN A2780; CELL STRAIN PTX10; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

AGED; ANTIGENS, NEOPLASM; ASCITES; CELL ADHESION MOLECULES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; DITERPENES, KAURANE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; FEMALE; FLAVANONES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 79955606571     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-010-9176-0     Document Type: Article

References (67)

1. MR Abedini EJ Muller R Bergeron DA Gray BK Tsang 2010 Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein Oncogene 29 11 25 19802016 10.1038/onc.2009.300 1:CAS:528:DC%2BD1MXht1WgsbzK
2. BB Aggarwal G Sethi A Nair H Ichikawa 2006 Nuclear factor-kB: a holy grail in cancer prevention and therapy Curr Signal Transduction Ther 1 25 52 10.2174/157436206775269235 1:CAS:528:DC%2BD28Xhs1Gis7g%3D
3. J Asakuma M Sumitomo T Asano T Asano M Hayakawa 2003 Selective Akt inactivation Cancer Res 63 1365 1370 12649200 1:CAS:528:DC%2BD3sXit1Sgur0%3D
4. F Balkwill A Mantovani 2001 Inflammation and cancer: back to Virchow? Lancet 357 539 545 11229684 10.1016/S0140-6736(00)04046-0 1:CAS:528: DC%2BD3MXhsVKltb0%3D (Pubitemid 32173595)
5. AA Beg D Baltimore 1996 An essential role for NF-kB in preventing TNF-alpha-induced cell death Science 274 782 784 8864118 10.1126/science.274. 5288.782 1:CAS:528:DyaK28XmsFOhu70%3D (Pubitemid 26398258)
6. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 15122205 10.1038/nrc1362 1:CAS:528: DC%2BD2cXjsFSlu7Y%3D (Pubitemid 38579480)
7. P Bremner M Heinrich 2002 Natural products as targeted modulators of the nuclear factor-B pathway J Pharm Pharmacol 54 453 472 11999122 10.1211/0022357021778637 1:CAS:528:DC%2BD38XjtlWgur4%3D (Pubitemid 34308488)
8. Cancer Research UK. Cancer incidence-UK statistics. 2010. http://info.cancerresearchuk.org/cancerstats/types/ovary/?a=5441
9. D Chaudhuri S Orsulic BT Ashok 2007 Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells Mol Cancer Ther 6 334 345 17237292 10.1158/1535-7163.MCT-06-0404 1:CAS:528:DC%2BD2sXmsVaktg%3D%3D (Pubitemid 46206698)
10. JQ Cheng AK Godwin A Bellacosa, et al. 1992 AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas Proc Natl Acad Sci USA 89 9267 9271 1409633 10.1073/pnas.89.19.9267 1:CAS:528:DyaK3sXks12itbs%3D
11. S Chen Q Ruan E Bedner A Deptala TC Hsieh F Traganos, et al. 2001 Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines Cell Prolif 34 293 304 11591177 10.1046/j.0960-7722.2001.00213.x 1:CAS:528:DC%2BD3MXotFWms70%3D (Pubitemid 32939476)
12. X Chen H Thakkar F Tyan S Gim H Robinson C Lee, et al. 2001 Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer Oncogene 20 6073 6083 11593415 10.1038/sj.onc.1204736 1:CAS:528:DC%2BD3MXnsVCjsb8%3D (Pubitemid 32955050)
13. S Chen J Gao HD Halicka X Huang F Oreganos Z Darzynkiewicz 2005 The gyrostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage Int J Oncol 26 579 588 15703811
14. S Chen J Gao HD Halicka X Huang F Traganos Z Darzynkiewicz 2008 Down-regulation of androgen-receptor and PSA by phytochemicals Int J Oncol 32 405 411 18202763 1:CAS:528:DC%2BD1cXitFWht7Y%3D (Pubitemid 351188307)
15. Y Chen N Lu Y Ling Y Gao L Wang Y Sun, et al. 2009 Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction Toxicology 259 10 17 19428938 10.1016/j.tox.2009.01.010 1:CAS:528:DC%2BD1MXktF2ns7g%3D
16. Z Darzynkiewicz F Traganos JM Wu S Chen 2000 Chinese herbal mixture PC SPES in treatment of prostate cancer (Review) Int J Oncol 7 729 736
17. M Dean Y Hamon G Chimini 2001 The human ATP-binding cassette (ABC) transporter superfamily J Lipid Res 42 1007 1017 11441126 1:CAS:528: DC%2BD3MXlt1Kru7k%3D (Pubitemid 32645780)
18. A Dey V Tergaonkar DP Lane 2008 Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-B pathways Nat Rev Drug Discov 7 1031 1040 19043452 10.1038/nrd2759 1:CAS:528:DC%2BD1cXhsVenu7%2FN
19. Z Duan DE LAmendola Y Duan RZ Yusuf MV Seiden 2005 Resistance to microtubule-stabilizing drugs involves two events β-tubulin mutation in one allele followed by loss of the second allele cancer Chemother Pharmacol 55 277 285 10.1007/s00280-004-0878-y 1:CAS:528:DC%2BD2MXhtVCnug%3D%3D (Pubitemid 40142893)
20. JB Easton PJ Houghton 2006 mTOR and cancer therapy (review) Oncogene 25 6436 6446 17041628 10.1038/sj.onc.1209886 1:CAS:528:DC%2BD28XhtVOlsrrN (Pubitemid 44582287)
21. SC Fas S Baumann JY Zhu M Giaisi MK Treiber 2006 Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis Blood 108 3700 3706 16931628 10.1182/blood-2006-03-011973 1:CAS:528:DC%2BD28Xht1Kgs7%2FP (Pubitemid 44864547)
22. M Fraser BM Leung XJ Yan HC Dan JQ Cheng BK Tsang 2003 p53 Is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells Cancer Res 63 7081 7088 14612499 1:CAS:528:DC%2BD3sXovVGlsLg%3D (Pubitemid 37413443)
23. P Giannakakou DL Sackett YK Kang Z Zhan JTM Buters T Fojo, et al. 1997 Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization JBC 272 17118 17125 10.1074/jbc.272.27.17118 1:CAS:528:DyaK2sXksVemt70%3D (Pubitemid 27289821)
24. T Giannopoulos S Butler-Manuel A Taylor N Ngeh H Thomas 2006 Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma Eur J Gynaecol Oncol 27 25 28 16550963 1:STN:280: DC%2BD287mtFyitg%3D%3D
25. AK Godwin JR Testa TC Hamilton 1993 The biology of ovarian cancer development Cancer 71 530 536 8420673 10.1002/cncr.2820710207 1:STN:280:DyaK3s7jtVCktA%3D%3D (Pubitemid 23021247)
26. G Gossnera M Choia L Tana S Fogorosa KA Griffitha M Kuenkera, et al. 2007 Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells Gynaecol Oncol 105 23 30 10.1016/j.ygyno.2006.11.009 (Pubitemid 46441453)
27. L Hu J Hofmann YB Lu G Mills RB Jaffe 2002 Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res 62 1087 1092 11861387 1:CAS:528:DC%2BD38XitVSmsbY%3D (Pubitemid 34160292)
28. T Ikezoe SS Chen XJ Tong D Heber H Taguchi HP Koeffler 2003 Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells Int J Oncol 23 1187 1193 12964003 1:CAS:528:DC%2BD3sXovV2nsrg%3D
29. T Ikezoe Y Yang K Bandobashi T Saito S Takemoto H Machida, et al. 2005 Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-KB signal pathways Mol Cancer Ther 4 578 586 15827331 10.1158/1535-7163.MCT-04-0277 1:CAS:528:DC%2BD2MXjtFegs7Y%3D (Pubitemid 40601839)
30. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics 2009 CA Cancer J Clin 59 225 240 19474385 10.3322/caac.20006
31. G Kallifatidis V Rausch B Baumann A Apel BM Beckermann, et al. 2009 Sulforaphane targets pancreatic tumour-initiating cells by NF-kB-induced antiapoptotic signalling Gut 58 949 996 18829980 10.1136/gut.2008.149039 1:CAS:528:DC%2BD1MXovFSktb0%3D
32. K Kaneko H Chiba N Horie T Kato, et al. 2010 Inhibition of prostaglandin E2 production by flavone and its related compounds In Vivo 24 55 58 20133976 1:CAS:528:DC%2BC3cXjslKgu70%3D
33. M Karin FR Greten 2005 NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5 749 759 16175180 10.1038/nri1703 1:CAS:528:DC%2BD2MXhtVGrurvL (Pubitemid 41400849)
34. MG Kelly AB Alvero R Chen D-A Silasi VM Abrahams S Chan, et al. 2006 TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer Cancer Res 66 3859 3868 16585214 10.1158/0008-5472.CAN-05-3948 1:CAS:528:DC%2BD28XjtVOru7k%3D
35. HP Kim KH Son HW Chang SS Kang 2004 Critical review, anti-inflammatory plant flavonoids and cellular action mechanisms J Pharmacol Sci 96 229 245 15539763 10.1254/jphs.CRJ04003X 1:CAS:528:DC%2BD2cXhtVequ7jL (Pubitemid 40013328)
36. SH Kim YS Juhnn YS Song 2007 Akt Involvement in paclitaxel chemoresistance of human ovarian cancer cells, ann. New York academy sci signal transduction pathways Part C Cell Signal Health Dis 1095 82 89 1:CAS:528:DC%2BD2sXks1Gkt7k%3D
37. Y Li TM Zhang 1987 Effect of oridonin on cell free DNA synthesis in vitro Zhongguo Yao Li Xue Bao 9 465 467
38. HL Lin WY Lui TY Liu CW Chi 2003 Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway Br J Cancer 88 973 980 12644839 10.1038/sj.bjc.6600788 1:CAS:528:DC%2BD3sXitFegsb8%3D (Pubitemid 36520889)
39. Y Liu L Chen TC Ko AP Fields EA Thompson 2006 Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT Oncogene 25 3565 3575 16462766 10.1038/sj.onc.1209403 1:CAS:528:DC%2BD28Xls1Kis7s%3D (Pubitemid 43901678)
40. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates. 2008;11:32-50.
41. TK Madhuri A Tailor SA Butler-Manuel 2009 Laparoscopic interval surgery for stage 4 primary fallopian tube carcinoma-a case report Gyne Surg Reprod Sci 15 321 326
42. U Mahlknecht PH Krammer M Li-Weber 2006 Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis Blood 108 3700 3706 16931628 10.1182/blood-2006-03-011973 (Pubitemid 44864547)
43. LS Marks RS DiPaola P Nelson S Cheen D Heber AS Belldegrun, et al. 2002 PC-SPES: Herbal formulation for prostate cancer Urology 60 369 375 12350462 10.1016/S0090-4295(02)01913-1 (Pubitemid 35292152)
44. WH Mondesire W Jian H Zhang J Ensor MC Hung, et al. 2004 Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin Cancer Res 10 7031 7042 15501983 10.1158/1078-0432.CCR-04-0361 1:CAS:528:DC%2BD2cXpslGlurY%3D (Pubitemid 39383055)
45. M Munz PA Baeuerle O Gires 2009 The emerging role of EpCAM in cancer and stem cell signaling Cancer Res 69 5627 5629 19584271 10.1158/0008-5472.CAN-09- 0654 1:CAS:528:DC%2BD1MXosV2msrs%3D
46. RB Ness JA Grisso C Cottreau J Klapper R Vergona JE Wheeler, et al. 2000 Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer Epidemiology 11 111 117 11021606 10.1097/00001648-200003000-00006 1:STN:280:DC%2BD3cvmsFKkuw%3D%3D (Pubitemid 30112009)
47. RB Ness DW Cramer MT Goodm SK Kjaer K Mallin BJ Mosgaard, et al. 2002 Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies Am J Epidemiol 155 217 224 11821246 10.1093/aje/155.3.217 (Pubitemid 34117299)
48. WK Oh PW Kantoff V Weinberg G Jones BI Rini MK Derynck, et al. 2004 Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer J Clin Oncol 22 3705 3712 15289492 10.1200/JCO.2004.10.195 1:CAS:528:DC%2BD2cXhtVCitLfF (Pubitemid 41095210)
49. GA Orr P Verdier-Pinard H McDaid SB Horwitz 2003 Mechanisms of Taxol resistance related to microtubules Oncogene 22 7280 7295 14576838 10.1038/sj.onc.1206934 1:CAS:528:DC%2BD3sXotlajtbc%3D (Pubitemid 37487160)
50. MP Ponnusamy B Sk 2008 Ovarian cancer: emerging concept on cancer stem cells J Ovarian Res 1 4 10.1186/1757-2215-1-4 19014671 10.1186/1757-2215-1-4
51. J Que Q Lian RME Oakley B Lim SK Lim 2007 PI3 K/Akt/mTOR-mediated translational control regulates proliferation and differentiation of lineage-restricted RoSH stem cell lines J Mol Signal 2 9 10.1186/1750-2187-2-9 17892597 10.1186/1750-2187-2-9 (Pubitemid 350020799)
52. CI Robbins MK Whiteman SD Hillis KM Curtis JA McDonald CH Banks 2009 Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis Cancer Epidemiol Biomark Prev 18 2035 2041 10.1158/1055-9965.EPI-09- 0156
53. A Salminen M Lehtonen T Suuronen K Kaarniranta J Huuskonen 2008 Terpenoids: natural inhibitors of NF-kB signalling with anti-inflammatory and anticancer potential Cell Mol Life Sci 65 2979 2999 18516495 10.1007/s00018-008-8103-5 1:CAS:528:DC%2BD1cXhtFOjtr3J
54. LA Solomon S Ali S Banerjee AR Munkarah RT Morris, et al. 2008 Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB J Ovarian Res 1 9 10.1186/1757-2215-1-9 19025644 10.1186/1757-2215-1-9
55. YC Song SY Kim YS Yuhnn YS Song 2007 Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells Ann NY Acad Sci 1095 26 34 17404014 10.1196/annals.1397.004 1:CAS:528:DC%2BD2sXks1Gkt74%3D (Pubitemid 47092433)
56. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Patrick A, et al. Overexpression of epithelial cell adhesion molecule (EpCAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gyne Oncology. 2006;103:483-88 (Pubitemid 44602156)
57. YJ Surh 2003 Cancer chemoprevention with dietary phytochemicals Nat Rev Cancer 3 768 780 14570043 10.1038/nrc1189 1:CAS:528:DC%2BD3sXotFChsLw%3D
58. PP Szotek R Pieretti-Vanmarcke PT Masiakos DM Dinulescu D Connolly, et al. 2006 Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness Proc Natl Acad Sci USA 103 11154 11159 16849428 10.1073/pnas.0603672103 1:CAS:528: DC%2BD28XnvVamurs%3D (Pubitemid 44156488)
59. M Trzpis PMJ McLaughlin LMFH de Lei MC Harmsen 2007 Epithelial cell adhesion molecule more than a carcinoma marker and adhesion molecule american j Pathology 171 386 396 1:CAS:528:DC%2BD2sXpsFaitLg%3D
60. I Vivanco CL Sawyers 2002 Thosphatidylinsitol 3- Kinase-Akt pathoway in human cancer Nat Rev Cancer 2 489 501 12094235 10.1038/nrc839 1:CAS:528:DC%2BD38XkvFKltLs%3D (Pubitemid 37328931)
61. CY Wang MW Mayo AS Jr Baldwin 1996 TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB Science 274 784 787 8864119 10.1126/science.274.5288.784 1:CAS:528:DyaK28XmsFOhu7Y%3D (Pubitemid 26398259)
62. AC Wang QB Su FX Wu PS Zhang XLand Liu 2009 Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells Eur J Clin Investig 39 157 164 10.1111/j.1365-2362.2008.02070.x 1:CAS:528:DC%2BD1MXjtFKnt7k%3D
63. NM Weir K Selvendiran VK Kutala L Tong S Vishwanath M Rajaram, et al. 2007 Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK Ancer Biol Ther 6 178 184 10.4161/cbt.6.2.3577 1:CAS:528:DC%2BD2sXhtVeqsbzI (Pubitemid 46641620)
64. KA West SS Castillo PA Dennis 2002 Activatiojn of PI3K/AKT pathway and chemortherapeutic resistance Drug Resist Update 5 234 248 10.1016/S1368-7646(02) 00120-6 1:CAS:528:DC%2BD3sXhtlShtbg%3D (Pubitemid 36132805)
65. Wilson AP. The development of human ovarian epithelial tumor cell lines from solid tumors and ascites. In: Pfragner R, Freshney RI, editors. Culture of human tumor cells. New York: Wiley; 2004. p. 1-50.
66. S Zhang C Balch MW Chan HC Lai D Matei JM Schilder, et al. 2008 Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res 68 4311 4320 18519691 10.1158/0008-5472.CAN-08- 0364 1:CAS:528:DC%2BD1cXmsFKmuro%3D
67. J Zhou A O'Brate A Zelnak P Giannakakou 2004 Survivin deregulation in -tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol Cancer Res 64 8708 8714 15574781 10.1158/0008-5472.CAN-04-2538 1:CAS:528:DC%2BD2cXhtVCjs7rL (Pubitemid 39552087)